ICMR Antimicrobial guidelines in immunecompromised hosts and solid organ transplant recipients

Published On 2017-03-18 08:47 GMT   |   Update On 2017-03-18 08:47 GMT

With advances in treatment of organ failure, auto-immune diseases and malignancies, an increasing population of immune compromised hosts and transplant recipients will develop infections and require care by the medical system. Such patients present unique challenges with regard to diagnosis and treatment, which often differ from the immune competent host. Moreover, these patients are likely to suffer repeated episodes of infections and consequently receive repeated courses of antimicrobial agents leading to higher level of antimicrobial resistance in pathogens.


Indian Council of Medical Research, Department of Health Research has issued the ICMR Antimicrobial guidelines in immunecompromised hosts and solid organ transplant recipients. Following are the major recommendations :



Case definition


An immune compromised host includes the following:




  • recipients of solid and stem cell organ transplants

  • congenital immune deficiency disorders

  • patients on medications that compromise cell mediated immunity eg corticosteroids, calcineurin inhibitors, mTOR pathway inhibitors, TNF-alpha antagonists, anti-thymocyte globulin and monoclonal antibodies like rituximab, adalimumab, etc.

  • Patients suffering from cancer, cystic fibrosis


Common pathogens


Immunocompromised hosts are at risk of developing opportunistic infections but also remain exposed to normal community acquired pathogens. Clinical presentation can be subtle and often difficult to diagnose in these hosts. The pathogens involved are by and large the same as those affecting immune competent hosts. Some specific pathogens unique to patients with compromised cell mediated immunity include Listeria monocytogenes, Nocardia spp, Pneumocystis jiroveci, Cytomegalovirus (CMV), Cryptococcus, Aspergillus spp, Strongyloides stercoralis



Prevalent AMR status in common pathogens


Table 1. Enterobacteriaceae isolates from blood. ICMR AMR data 2014.



Note : Ec : Escherichia coli; Ks : Klebsiella spp.; Es : Enterobacter spp



Table 2. Salmonella Typhi isolates from blood ICMR AMR Data 2014





























































AMAPGIMER, Chandigarh ‘n’ 109




No. R (%)
AIIMS, New Delhi ‘n’ 22




No. R
CMC, Vellore ‘n’ 71




No. R (%)
JIPMER, Puducherry ‘n’ 7




No. R
National ‘n’ 209




No.R %)
Ampicillin9 (8.3)02 (2.8)011 (5.3)
Cefixime0 (0)00 (0)00 (0)
Ceftriaxone0 (0)00 (0)00 (0)
Chloramphenicol3 (2.8)01 (1.4)04 (1.9)
Ciprofloxacin56 (51.4)1567 (94.4)7145 (69.4)
Trimethoprim-sulphamethoxazole0 (0)03 (4.2)0 3 (1.4)

Note : If No. Tested is ≥30, No. R (%) given. If No. tested <30, only No. R given.



Table 3. Staphylococcus aureus ICMR AMR Data 2014



*The 4 numbers listed as Vancomycin Resistant (R) are VISA isolates.


No VRSA was isolated during the year 2014 at JIPMER.


Cefoxitin : Surrogate marker for Methicillin.



Table 4. Enterococcus faecalis ICMR AMR Data 2014




Table 5. Enterococcus faecium ICMR AMR Data 2014.




Table 6. Pseudomonas aeruginosa ICMR AMR Data 2014













































































































AMAPGIMER, Chandigarh ‘n’ 75 R (%)AIIMS, New Delhi ‘n’ 102 R (%)JIPMER, Puducherry ‘n’ 113 R (%)CMC, Vellore ‘n’ 84 R (%)National ‘n’ 374 R %
Amikacin2749382135
Aztreonam62553048
Cefepime52572041
Cefoparazone -sulbactam39413038
Ceftazidime6451512347
Colistin34210
Imipenem1754482537
Levofloxacin44422336
Meropenem74412347
Netilmicin66452245
Piperacillin-tazobactam44672546
Tobramycin56431833

Table 7. Acinetobacter baumannii susceptibility pattern 2014





























































































































AMAPGIMER, Chandigarh ‘n’ 209 R (%)AIIMS, New Delhi ‘n’ 143 R (%)JIPMER, Puducherry ‘n’ 157 R (%)CMC, Vellore ‘n’ 90 R (%)National ‘n’ 599 R %
Amikacin7783598475
Aztreonam87938487
Cefepime9886756181
Cefoparazone -sulbactam8923224757
Ceftazidime9986686884
Colistin1642222
Imipenem5283626463
Levofloxacin86686073
Meropenem5086596162
Netilmicin795669
Piperacillin-tazobactam73867183
Tobramycine615255
Tobramycin54645858
Trimethoprim-sulphamethoxa zole466355

Table 8 Central nervous system infections


























Clinical conditionCommon pathogensEmpiric antimicrobial agentsAlternative antimicrobial agentsComments
Acute bacterial meningitisPneumococcus, Listeria monocytogenes, H.influenzae, MeningococcusCeftriaxone 2 gm IV q 12h/ Cefotaxime 2 gm IV q 4-6h

+

Ampicillin 2gm IV q4h
Moxifloxacin 400mg IV q 24h

or

Meropenem 2gm IV q 8h
Exclude TB, Cryptococcus

Vancomycin not required due to low level of penicillin resistance in Pneumococcus

If penicillin allergic, use cotrimoxazole 15 mg/kg/day (TMP component) or meropenem 2gm IV q 8h to cover for Listeria

Duration: 10-14 days, 21 days for Listeria or Gram negative infection
Brain abscess, subural empyema

 

 

 

 

 

 
Streptococci, Bacteroides, Enterobacteriace -ae, Staph aureus

 

 

 

 

 

 

Nocardia spp

 

 

 
Ceftriaxone 2 gm IV q12h/ Cefotaxime 2 gm IV q 4-6h

+

Metronidazole 1 gm IV q 12h

Duration based upon clinical & radiological response, minimum 8 weeks

 

Co-trimoxazole 15 mg/kg/dose (trimethoprim component) IV or PO, plus imipenemcilastatin 500 mg q6h
Meropenem 2gm IV q 8h

 

 

 

 

 

 

 

 

 

Linezolid 600 mg IV or PO q12h

 

 
Exclude TB, Nocardia, Aspergillus

Aspiration/surgical drainage required unless abscess <2.5cm & patient neurologically stable

 

 

 

 

Duration: 3-6 weeks of IV therapy, followed by 12 months of oral therapy

 

Table 9 Respiratory tract infections






















































ConditionOrganismsEmpiric antibioticsAlternative antibioticsComments
Pneumonia

 

 

 

 

 

 

 

 

 

 

 

 

 
S. pneumoniae, H.influenzae, Legionella,

E.coli,

Klebsiella, Pseudomonas, S.aureus

 

 

 

 

Pneumocystis

 

 

 
Ceftriaxone 2 g IV od or

Piperacillin-tazobactam 4.5 gm IV q 6h plus either

azithromycin 500 mg PO/IV OD or doxycycline 100 mg PO BD Duration 5-8 days

 

Cotrimoxazole (trimethoprim component 15 mg/kg /day) Duration: 14 days, 21 days in patients with HIV
Imipenem- cilastatin 500 mg q6h

 

 

 

 

 

 

Clindamycin 600 mg IV q8h+ Primaquine 15 mg q12h(if sulpha allergy)

 

 
If MRSA is a concern,

add linezolid 600 mg IV/PO BD

Avoid fluoroquinolones unless

TB excluded

Exclude TB, influenza, Nocardia, fungi (Aspergillus,

Mucor, Cryptococcus), Strongyloides

hyperinfection

De-escalate to

narrow spectrum agent on

receipt of senstivity report

 
Lung abscess, empyema

 
Pneumococcus, Strep milleri group, E.coli, Klebsiella, Pseudomonas, S.aureus, anaerobesPiperacillin-tazobactam 4.5 gm IV q 6h Duration: 3-4 weeks

 
Cefoperazone-sulbactam 3 gm IV q 12h + clindamycin 600-900 mg IV q 8hDrainage of pleural space essential for empyema

 

 
Acute bacterial pharyngitisGroup A ß- hemolytic streptococci (GABHS)Benzathine penicillin 12 laks units IM or amoxicillin 500 mg PO q8h for 10 daysMost cases viral, confirm GABHS on culture before treating
Head and neck space infectionsPolymicrobial (Str pyogenes, Staph aureus, oral anaerobes)Clindamycin 600 mg IV q8h or Amox-clav 1.2 gm IV/PO q8hPiperacillin-tazobactam 4.5 gm IV q 6hDuration: At least 1 week

 
Acute sinusitisViral, S.pneumoniae, H.influenzae, M. catarrhalisAmox-clav 1.2 gm IV/PO q8hfor 7 daysPiperacillin-tazobactam 4.5 gm IV q 6hExclude fungi

(Aspergillus, Mucor)
Acute bronchitisViral--Antibiotics not required

Table 10 Gastrointestinal & intra-abdominal infections











































































ConditionOrganismsEmpiric antibioticsAlternative antibioticsComments
Acute gastroenteritis

 

 

Food poisoning

 
Viral, entero toxigenic & entero pathogenic

E. coli

S. aureus, B. cereus, C. botulinum
none

 

 

 

 
none

 

 

 

 
Rehydration (oral/IV) essential

 

 

 

 
Cholera

 

 

 
V.cholerae

 

 

 
Doxycycline 300 mg PO stat

 

 
Azithromycin 1 gm PO stat

or

Ciprofloxacin 500 mg BD for 3 days
Rehydration (oral/IV) essential

 

Antibiotics are adjuvant therapy
Bacterial dysentery

 

 
Shigella, Campylobacter, non typhoidal salmonellosis, Shiga toxin producing E. coliCeftriaxone 2 gm IV OD for 5 days

 
Azithromycin 1 gm od x 3d

 
Amoebic dysenteryE. histolyticaMetronidazole 500 to 750 mg IV q8h for 7-10 daysTinidazole 2 gm PO OD for 3 daysAdd diloxanide furoate 500 mg tds for 10d
Enteric feverS.Typhi, S.Paratyphi AOutpatients: TMP-SMX4 1 DS tablet BD for 2 weeks or azithromycin 500 mg BD for 7 daysInpatients: Ceftriaxone 2 g IV OD for 2 weeks
Biliary tract infections (cholangitis, cholecystitis)

 

 

 
Enterobacteriacea (E.coli, Klebsiella)

 

 

 

 
Piperacillin-tazobactam 4.5 gm IV q 6h or Cefoperazone-sulbactam 3 gm IV q 12h or Ertapenem 1 gm IV OD

 

 
Imipenem-cilastatin 500 mg q6h or meropenem 1 gm IV q8h

 

 
Surgical or endoscopic intervention to be considered if there is biliary obstruction. De-escalate to narrow spectrum agent on receipt of sensitivities.
Hospital acquired diarrheaC. difficile

 
Mild-moderate: Metronidazole 400 mg po qid for 10 days Severe: vancomycin 250 mg po q 6h empiricallyConfirm by PCR or GDHEIA test

 
Spontaneous bacterial peritonitis

 
Enterobacteriaceae (E.coli, Klebsiella)Piperacillin-tazobactam 4.5 gm IV q 6h or Cefoperazone-sulbactam 3 gm IV q 12h or Ertapenem 1 gm IV OD Duration: 7-10 daysImipenem-cilastatin 500 mg IV q6h or meropenem 1 gm IV q8hDe-escalate to narrow spectrum agent on receipt of sensitivities.
Secondary peritonitis, intra-abdominal abscessEnterobacteriaceae (E.coli, Klebsiella), Bacteroides

 
Piperacillin-tazobactam 4.5 gm IV q 6h or Cefoperazone-sulbactam 3 gm IV q 12h or Ertapenem 1 gm IV ODImipenem-cilastatin 500 mg IV q6h or meropenem 1 gm IV q8hSource control is important. De-escalate to narrow spectrum agent on receipt of sensitivities.

Table 11 Skin & soft tissue infections

































Condition Organisms Empiric antibioticsAlternative antibioticsComments
CellulitisStrep. pyogenes, S.aureusCefazolin 2 gm IV q8h.Clindamycin 600-900 mg IV q8hDuration: 5-7 days. Can switch to oral therapy once improving
Abscess, carbuncleS.aureusCefazolin 2 gm IV q8hClindamycin 600-900 mg IV TDS or Linezolid 600 mg q 12hGet pus cultures. MRSA coverage advisable for children <5 or severe infections
Necrotizing fasciitis

 

 
Strep. pyogenes, Staph aureus (monomicrobial), Anaerobes, Enterobacteriaceae (polymicrobial)Piperacillin-tazobactam 4.5 gm IV q 6h or Cefoperazone-sulbactam 3 gm IV q 8h plus Clindamycin 600-900 mg IV q8hImipenem-cilastatin 500 mg IV q6h or meropenem 1 gm IV q8h + Clindamycin 600-900 mg IV q8hEarly surgical intervention crucial. De-escalate to narrow spectrum agent on receipt of sensitivities.

Table 12 Urinary tract infections

































Condition OrganismsEmpiric antibioticsAlternative antibioticsComments
CystitisEnterobacteriaceae (E.coli, Klebsiella)Nitrofurantoin 100 mg BD for 5 daysCo-trimoxazole DS BD or ciprofloxacin 500 mg BD for 3 daysObtain urine cultures before antibiotics & modify therapy based on senstivity report
Acute pyelonephritisEnterobacteriaceae (E.coli, Klebsiella)Piperacillin-tazobactam 4.5 gm IV q 6h or Cefoperazone-sulbactam 3 gm IV q 12h or Ertapenem 1 gm IV OD. Treat for 10-14 days.Imipenem-cilastatin 500 mg IV q6h or meropenem 1 gm IV q8hObtain urine cultures before antibiotics & switch to a narrow spectrum agent based on senstivity report
Acute prostatitis

 

 

 

 

 

Chronic bacterial prostatitis

 

 
Enterobacteriaceae (E.coli, Klebsiella)

 

 

 

 

 

Enterobacteriaceae (E.coli, Klebsiella)

 

 
Piperacillin-tazobactam 4.5 gm IV q 6h or Cefoperazone-sulbactam 3 gm IV q 12h or Ertapenem 1 gm IV OD or

 

 

Ciprofloxacin 750 mg po bid

 

 
TMP/SMX DS PO q12h

 

 

 

 

 

 

 
Obtain urine and blood cultures before antibiotics & switch to narrow spectrum agent based on sensitivities. Treat for 4 weeks.

Therapy based on urine and prostatic massage cultures obtained before antibiotics. Treat for 4-6 weeks

Table 13 Bone & joint infections


























ConditionOrganismsEmpiric antibioticsAlternative antibioticsComments
Acute osteomyelitis, septic arthritis

 

 

 
S.aureus, Strep. pyogenes, Enterobacteriaceae

 

 

 

 
Cefazolin 2 g IV q8h

or

Ceftriaxone 2 g IV od

 

 
Piperacillin-tazobactam 4.5 gm IV q 6h or Cefoperazone-sulbactam 3 gm IV q 12h plus Clindamycin 600-900 mg IV TDS

 
Treat based on culture of blood/synovial fluid/bone biopsy. Surgical debridement essential. Duration: 3-4 weeks (from initiation or last major debridement)
Chronic osteomyelitis, chronic infective arthritisNo empiric therapy

 
Definitive treatment guided by bone/synovial biopsy culture.

Table 14 Severe sepsis and septic shock of undetermined source























ConditionOrganismsEmpiric antibioticsComments
Community acquiredEnterobacteriace ae, Pseudomonas, Staph aureusImipenem- cilastatin 1 g IV q8h or meropenem 1 g IV q8hAdd vancomycin if Staph aureus is a concern. Add colistin if high local prevalence of carbapenem resistant organisms or previously colonized.
Hospital acquiredEntero-bacteriaceae, Pseudomonas, Acinetobacter, Staph aureusImipenem 1g IV q8h or meropenem 1g IV q8h plus Vancomycin 1g IV q12h plus Colistin 9 mu IV stat then 4.5 mu IV q12hBroaden spectrum if prior antibiotic exposure. De-escalate to narrow spectrum agent on receipt of sensitivities.

Table 15 Post-op infections following solid organ transplant (kidney, liver, heart, lung)















































ConditionOrganismsEmpiric antibioticsAlternative antibioticsComments
Post-op fever with hemodynamic stabilityUsually not due to infectionNone

 
Look for hematoma, DVT, transfusion related fever, rejection
Surgical site infectionStaph aureus, Entero-bacteriaceae, PseudomonasTreat based on culture and sensitivities
VAP/HAP

 

 

 

 
Entero-bacteriaceae, Pseudomonas, Acinetobacter

 

 
Piperacillin-tazobactam 4.5 g IV q6h or Cefoperazone-sulbactam 3 g IVq8h. Add colistin if high local prevalence of carbapenem resistant organisms.Imipenem-cilastatin 1g IV q8h or meropenem 1g IV q8h

 
De-escalate to narrow spectrum agent on receipt of sensitivities.

 

 
CLABSI

 

 

 

 
Entero-bacteriaceae, Pseudomonas, Acinetobacter, Staph aureus

 

 
Piperacillin-tazobactam 4.5 g IV q6h or cefoperazone-sulbactam 3 g IVq8h plus vancomycin 1g IV q12h. Add colistin if high local prevalence of carbapenem resistant organisms.Imipenem-cilastatin 1g IV q8h or meropenem 1g IVq8h

 

 
Obtain blood cultures before starting antibiotics. Deescalate to narrow spectrum agent on receipt of sensitivities.

 
CA-UTI

 

 
ntero-bacteriaceae, enterococci

 
Piperacillin-tazobactam 4.5 g IV q6h or cefoperazone-sulbactam 3 g IVq12hImipenem-cilastatin 1g IV q8h or meropenem 1g IV q8hObtain blood and urine cultures before starting antibiotics. Deescalate to narrow spectrum agent on receipt of sensitivities.

Guidelines by Indian Council of Medical Research :


Dr Soumya Swaminathan, Director General, Indian Council of Medical Research Secretary, Department of Health Research

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

NICE Guidelines on Latent TB